Jubilant Therapeutics is preparing for Phase II and first-in-human trials later in 2023, with two Orphan Drug Designations, an advantageous safety profile and enhanced therapeutic indices. The company's pipeline is generated 100% in-house using its Therapeutic Index and Brain Exposure Optimization (TIBEO) discovery engine, which permits the identification of candidate molecules with enhanced therapeutic indices and the ability to penetrate the brain to achieve pharmacologically active concentrations. Jubilant's core strength lies in drug discovery. Its strategic objective is to develop candidates through clinical proof of concept and then partner those assets with companies that have the expertise to advance them through late-stage clinical development and to market.
The lead program, JBI-802, is an oral inhibitor of coREST, an emerging target implicated in hematological tumors like essential thrombocythemia (ET), certain neuroendocrine tumors and resistance to immune-checkpoint inhibition. In preclinical testing, JBI-802's targeting of coREST in animal models generated anti-tumor activity superior to that achieved by inhibitors of either LSD1 or HDAC6 alone. JBI-802 showed a favorable safety profile especially, with